7Baggers
Quarterly
Annual
    Unit: USD2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 
      
    		                               
      operating activities
    		                               
      net income
    		-126,902,000 -124,119,000 -132,970,000 -114,753,000 -107,192,000 -99,026,000 -101,802,000 -119,473,000 -99,353,000 183,383,000 -109,781,000 -98,678,000 -103,299,000 -58,794,000 -65,220,000 -75,261,000 -84,588,000 -60,691,000 -70,041,000 244,885,000 -58,228,000 -58,758,000 -56,763,000 -54,025,000 -46,260,000 -58,337,000 -38,992,000 77,533,000 -35,371,000 -54,724,000 -23,678,000 
      adjustments to reconcile net income to net cash from operating activities:
    		                               
      depreciation and amortization
    		2,947,000 3,045,000 2,325,000 1,853,000 1,838,000 1,942,000 2,162,000 2,177,000 2,217,000 2,285,000 10,047,000 4,091,000 2,141,000 2,072,000 2,079,000 2,094,000 2,187,000 2,204,000 2,108,000 2,121,000 2,156,000 2,145,000 2,109,000 2,055,000 1,890,000 1,643,000 2,403,000 2,379,000    
      stock–based compensation expense
    		25,135,000 25,387,000 25,160,000  24,860,000 25,100,000 27,840,000  27,460,000 26,570,000 28,084,000  24,579,000 23,936,000 26,145,000  20,998,000 21,136,000 21,028,000  13,252,000 12,484,000 10,785,000  8,901,000 13,714,000 6,874,000  5,510,000   
      net accretion of discounts on marketable securities
    		-2,026,000 -2,697,000 -3,888,000 -6,165,000 -8,378,000                           
      non-cash adjustment to operating lease expense
    		-1,144,000 -1,112,000 -1,049,000 -1,049,000 -1,049,000 -1,019,000 -957,000 -957,000 -957,000 -928,000 -877,000 -863,000 -865,000 -840,000 -783,000 -783,000 -782,000 -728,000 -691,000 -691,000 -691,000           
      right-of-use asset amortization for finance lease
    		915,000 911,000 887,000 766,000                            
      non-cash gain from divestiture of small molecule programs
    		   0 0 0 -14,537,000                         
      changes in operating assets and liabilities:
    		                               
      prepaid expenses and other current assets
    		1,363,000 24,957,000 -28,607,000                             
      other non-current assets
    		-1,717,000 3,965,000 -943,000 1,781,000                            
      accounts payable
    		-4,069,000 2,596,000 -2,639,000 1,286,000 -4,372,000 3,888,000 635,000 -2,081,000 -3,960,000 4,774,000 3,698,000 -1,715,000 1,902,000 839,000 1,248,000 -78,000 782,000 2,378,000 623,000 -1,770,000 891,000 -452,000 -292,000 567,000 -837,000 -662,000 1,965,000 -1,761,000 -5,859,000 8,045,000 -951,000 
      accruals and other current liabilities
    		1,889,000 -7,674,000 -6,477,000 11,287,000 14,246,000 -10,477,000 2,321,000 14,313,000 734,000 -32,209,000 19,810,000 4,027,000 9,332,000 5,865,000 -8,306,000 7,768,000 6,491,000 1,277,000 -10,804,000 17,226,000 7,095,000 1,612,000 -3,827,000         
      deferred research and development funding liability
    		-3,687,000                               
      net cash from operating activities
    		-107,296,000 -75,298,000 -131,468,000 -83,715,000 -59,139,000 -91,220,000 -113,620,000 -98,657,000 -87,363,000 -113,169,000 -58,802,000 -72,663,000 -57,046,000 -42,898,000 -72,109,000 -65,494,000 -41,434,000 -54,221,000 -50,240,000 513,915,000 86,000 -43,357,000 -54,492,000 -47,643,000 -30,435,000 -43,175,000 -30,323,000 93,185,000 -34,822,000 -41,824,000 33,577,000 
      capex
    		1,378,000 -4,278,000 -5,078,000 -5,092,000 -3,884,000 -4,786,000 -2,150,000 -2,235,000 -2,068,000 -5,850,000 -2,786,000 -4,849,000 -6,050,000 -2,893,000 -4,041,000 -3,053,000 -1,875,000 -772,000 -2,800,000 -1,195,000 -706,000 -315,000 -879,000 0 -2,847,000 -10,271,000 -2,028,000 -1,437,000 -847,000 -572,000 -537,000 
      free cash flows
    		-105,918,000 -79,576,000 -136,546,000 -88,807,000 -63,023,000 -96,006,000 -115,770,000 -100,892,000 -89,431,000 -119,019,000 -61,588,000 -77,512,000 -63,096,000 -45,791,000 -76,150,000 -68,547,000 -43,309,000 -54,993,000 -53,040,000 512,720,000 -620,000 -43,672,000 -55,371,000 -47,643,000 -33,282,000 -53,446,000 -32,351,000 91,748,000 -35,669,000 -42,396,000 33,040,000 
      investing activities
    		                               
      purchases of marketable securities
    		-50,629,000 0 -137,926,000 -173,701,000 -100,461,000 -121,645,000 -834,157,000 -413,718,000 -498,141,000 -378,127,000 -523,714,000 -486,710,000 -122,870,000 -141,123,000 -364,337,000 -231,447,000 -344,195,000 -384,191,000 -463,105,000 -597,945,000 -363,916,000 -170,452,000 -153,155,000  -75,110,000 -34,219,000 -109,810,000     
      maturities and sales of marketable securities
    		107,081,000 162,213,000 161,752,000  198,000,000 225,000,000 383,120,000 489,000,000 601,118,000 552,044,000 433,785,000 364,000,000 144,339,000 232,647,000 250,500,000 193,750,000 293,062,000 482,500,000 440,500,000 231,800,000 152,500,000 140,356,000 140,701,000    103,791,000 97,327,000 84,525,000 64,750,000 27,299,000 
      purchases of property and equipment
    		1,378,000 -4,278,000 -5,078,000 -5,092,000 -3,884,000 -4,786,000 -2,150,000 -2,235,000 -2,068,000 -5,850,000 -2,786,000 -4,849,000 -6,050,000 -2,893,000 -4,041,000 -3,053,000 -1,875,000 -772,000 -2,800,000 -1,195,000 -706,000 -315,000 -879,000  -2,847,000 -10,271,000 -2,028,000     
      net cash from investing activities
    		57,830,000 157,935,000 18,748,000 172,207,000 93,655,000 98,569,000 -453,187,000 73,047,000 100,909,000 168,067,000 -92,715,000 -127,559,000 15,419,000 88,631,000 -117,878,000 -40,750,000 -53,008,000 97,537,000 -25,405,000 -367,340,000 -212,122,000 -30,411,000 -13,333,000 42,385,000 49,493,000 63,881,000 -8,047,000 -61,403,000 44,727,000 30,528,000 -301,274,000 
      financing activities
    		                               
      proceeds from issuance of common stock and pre-funded warrants, net of issuance costs of 480
    		                               
      proceeds from exercise of awards under equity incentive plans
    		583,000 4,057,000 595,000 4,155,000 5,456,000 6,756,000 1,022,000 4,705,000 2,492,000 9,019,000 1,604,000 3,436,000 5,154,000 4,402,000 1,463,000 5,168,000 3,315,000 7,043,000 3,822,000 9,522,000 5,753,000 3,415,000 1,965,000 2,034,000 679,000 2,569,000 908,000  658,000   
      payments for finance lease right-of-use asset
    		-1,361,000 -2,434,000 -4,357,000 -8,323,000                            
      net cash from financing activities
    		-778,000 1,623,000 -3,762,000 -4,168,000 -18,559,000 6,756,000 500,275,000 4,705,000 2,492,000 9,019,000 1,604,000 299,651,000 5,154,000 4,402,000 1,463,000 5,168,000 3,315,000 7,043,000 3,822,000 9,522,000 425,899,000 3,415,000 195,913,000 2,034,000 679,000 2,569,000 908,000 1,690,000 658,000 1,432,000 93,239,000 
      net decrease in cash, cash equivalents and restricted cash
    		-50,244,000 84,260,000 -116,482,000  15,957,000 14,105,000 -66,532,000 -20,905,000 16,038,000 63,917,000 -149,913,000  -36,473,000 50,135,000 -188,524,000           23,275,000 -37,462,000    -174,458,000 
      cash, cash equivalents and restricted cash at beginning of period
    		0 0 176,535,000  0 0 128,681,000  0 0 219,544,000  0 0 294,977,000  0 0 508,644,000  0 0 80,949,000  0 0 78,623,000  0 0 218,910,000 
      cash, cash equivalents and restricted cash at end of period
    		-50,244,000 84,260,000 60,053,000  15,957,000 14,105,000 62,149,000  16,038,000 63,917,000 69,631,000  -36,473,000 50,135,000 106,453,000  -91,127,000 50,359,000 436,821,000  213,863,000 -70,353,000 209,037,000  19,737,000 23,275,000 41,161,000  10,563,000 -9,864,000 44,452,000 
      supplemental disclosures of cash flow information
    		                               
      equity consideration received in the divestiture of small molecule programs
    		   0 0 0 15,000,000                         
      deferred research and development funding liability, less current portion
    		  16,733,000                             
      right-of-use asset obtained in exchange for new finance lease liabilities
    		  2,876,000                             
      cash paid for finance lease interest
    		  181,000 181,000                            
      property and equipment purchases accrued but not yet paid
    		  488,000 929,000 35,000 -1,719,000 1,947,000 -5,677,000 5,655,000 -5,500,000 6,075,000 1,180,000 -37,000 207,000 114,000 564,000 -200,000   35,000 30,000    -662,000 593,000 1,569,000 298,000   246,000 
      issuance costs incurred but not yet paid
    		      394,000                         
      stock-based compensation expense
    		                              2,925,000 
      other non-cash items
    		           12,000 46,000      -2,000 20,000 57,000 14,000 -53,000 76,000 -114,000       
      prepaid expenses and other assets
    		     -1,570,000 -18,766,000 -6,004,000 87,000 3,612,000 -1,789,000 -1,374,000 13,365,000 -15,993,000 1,242,000 -20,914,000 16,104,000 -14,356,000 6,301,000 -14,388,000 25,000 6,248,000 -2,454,000 863,000 3,108,000 -145,000 2,849,000 -12,911,000 -3,661,000 -105,000 -1,613,000 
      contract liabilities
    		           -23,000 -3,375,000 0 -27,915,000 -1,324,000 -4,426,000 -7,144,000 969,000 -1,333,000 -9,276,000 -5,575,000 -3,069,000  -1,181,000 -839,000 -777,000     
      related party contract liability
    		              -2,226,000 -1,191,000 -860,000 -794,000 -892,000 252,564,000            
      other non-current liabilities
    		                               
      maturities of marketable securities
    		                        127,450,000       
      proceeds from public offering of common stock, net of issuance costs
    		                   0 0 0 193,948,000         
      net increase in cash, cash equivalents and restricted cash
    		               -101,076,000 -91,127,000 50,359,000 -71,823,000 156,097,000 213,863,000 -70,353,000 128,088,000 -3,224,000        
      cash, cash equivalents and restricted cash at beginning of year
    		                               
      cash, cash equivalents and restricted cash at end of year
    		                               
      increase in right-of-use asset due to lessor assets
    		   0                            
      cash paid during the year for income taxes
    		                               
      related-party contract liability
    		        -1,268,000 -289,123,000 -141,000  -184,000                   
      proceeds from issuance of common stock and pre-funded warrants, net of issuance costs of 480k
    		    0 0 499,253,000                         
      non-cash recognition of new finance lease
    		                               
      cash paid during the period for income taxes
    		        0 0 4,000                     
      net amortization of premiums and (discounts) on marketable securities
    		      -10,516,000 -12,243,000 -12,323,000 -11,533,000 -7,853,000                -1,317,000     
      proceeds from issuance of common stock in connection with collaboration agreements
    		                               
      net amortization of premiums on marketable securities
    		            -688,000 491,000 1,627,000                 
      tenant improvements provided by the landlord
    		                       0 2,000 0 11,341,000 10,197,000    
      net amortization of premiums (discounts) on marketable securities
    		                               
      net amortization of discounts on marketable securities
    		                 2,495,000 1,161,000  -49,000 -418,000 -607,000  -1,298,000       
      deferred rent
    		                           4,620,000 157,000 -1,114,000 -225,000 
      payments of issuance costs related to issuance for common stock
    		                           0 0   
      payments of issuance costs related to issuance for preferred stock
    		                           0 0   
      proceeds from issuance of common stock in connection with the biogen stock purchase agreement
    		                               
      non-cash operating lease expense
    		                      321,000         
      operating lease liability
    		                      -642,000         
      net amortization of (discounts) and premiums on marketable securities
    		                               
      accrued and other current liabilities
    		                       -1,376,000 4,763,000 2,706,000 -4,593,000 6,474,000 4,042,000 1,854,000 -3,257,000 
      contract liability
    		                           11,667,000 -1,195,000 -1,648,000 59,953,000 
      purchase of marketable securities
    		                           -157,293,000 -38,951,000 -33,650,000 -328,036,000 
      purchase of property and equipment
    		                           -1,437,000 -847,000 -572,000 -537,000 
      issuance of common stock in connection with the takeda collaboration agreement
    		                               
      proceeds from issuance of common stock, net of issuance costs
    		                               
      proceeds from issuance of convertible preferred stock, net of issuance costs
    		                               
      deferred ipo costs incurred but not yet paid
    		                               
      convertible preferred stock issuance costs incurred but not yet paid
    		                               
      non-cash rent expense
    		                        593,000 475,000 1,265,000     
      gain on disposal of property and equipment
    		                            0 8,000 -44,000 
      payments of issuance costs related to issuance of common stock
    		                              -1,342,000 
      payments of issuance costs related to issuance of preferred stock
    		                              -44,000 
      (gain) loss on disposal of property and equipment
    		                               
      fair value of common stock issued in connection with asset acquisition
    		                               
      purchase of other investments
    		                               
      proceeds from exercise of common stock options
    		                              219,000 
      net increase in cash and cash equivalents
    		                               
      net amortization of premiums and discounts on marketable securities
    		                            -772,000 -705,000 -387,000 
      issuance of common stock in connection with collaboration agreement
    		                            0 0 94,406,000 
      deferred ipo costs accrued but not yet paid
    		                               
      depreciation
    		                             1,855,000 854,000 
      cash from operating activities
    		                               
      cash from investing activities
    		                               
      cash from financing activities
    		                               
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.